Actavis Faces Wait Until 2027 On US Pennsaid
Horizon’s Patent Has Been Upheld On Appeal
Teva’s Actavis has lost the patent battle over osteoarthritis drug Pennsaid 2% due to a lack of “clear and convincing evidence” and “unpersuasive arguments” over obviousness.
You may also be interested in...
Unsatisfied with a US Court of Appeals upholding a ruling in favor of Teva's Actavis that several Pennsaid 2% patents were invalid, Horizon Therapeutics sought to have the case reheard en banc. However, the request has been refused.
Boehringer Ingelheim, which holds a 16.4% share of Hikma along with voting rights, is ready to exit the company altogether as Hikma decides to buy back £295m worth of shares. Hikma has invited new investors, expressing confidence in its future plans.
Currently serving at the WHO, Emer Cooke is set to return to the EMA later this year in the role of executive director. She will have to tackle challenges posed by Brexit, COVID-19 and recent agency restructuring.